Gut Microbiota Shapes Radiation Injury and Recovery Through Three Key Pathways
A 2025 review maps how gut bacteria and their metabolites protect against radiotherapy damage—and how microbial therapies could transform cancer treatment.
Summary
Radiotherapy treats over half of all cancers but causes significant collateral damage—enteritis, mucositis, hematological injury, and cardiopulmonary harm. This 2025 review in Gut Microbes systematically examines how gut microbiota and their metabolites regulate these injuries through three core mechanisms: intestinal stem cell regeneration via Wnt/β-catenin and PI3K/AKT/mTOR signaling, immune modulation via TLR and NF-κB pathways, and oxidative stress control via Nrf2. Specific metabolites—SCFAs, indole derivatives, imidazole propionate, and urolithin A—demonstrate protective effects across multiple organs. The authors also evaluate interventions including probiotics, prebiotics, fecal microbiota transplantation, and engineered microbial therapies, arguing these represent a new frontier for precision, microbiome-guided radiotherapy strategies.
Detailed Summary
Radiotherapy is administered to more than 50% of cancer patients, yet its therapeutic benefit is routinely compromised by toxic side effects—radiation-induced enteritis, oral mucositis, hematopoietic injury, and cardiopulmonary damage. This comprehensive 2025 review in Gut Microbes investigates the mechanistic links between gut microbiota, microbial metabolites, and radiation-induced injury, synthesizing preclinical and clinical evidence to map a new therapeutic landscape.
The authors identify radiation's primary damage mechanisms as DNA strand breaks, water radiolysis-generated reactive oxygen species (ROS), mitochondrial dysfunction, and inflammatory cascades triggered by damage-associated molecular patterns (DAMPs) activating TLR and NLRP3 inflammasome signaling. Critically, gut microbiota modulate all of these pathways. For example, propionate reduces phosphorylation of DNA damage markers (p53, 53BP1) and lowers ROS in intestinal and bone marrow stem cells of irradiated mice. Lactobacillus plantarum enhances intestinal stem cell DNA repair via the FXR-FGF15 axis, evidenced by reduced γ-H2AX levels, while Lactobacillus rhamnosus GG (LGG) suppresses the cGAS/STING pathway to attenuate inflammation.
Three signaling pathways emerge as central regulators. First, Wnt/β-catenin and PI3K/AKT/mTOR pathways govern intestinal stem cell (ISC) regeneration and tumor cell apoptosis; α-linolenic acid and lactate activate Wnt/β-catenin to promote Lgr5+ ISC proliferation, while urolithin A and butyrate enhance tumor apoptosis. Second, TLR activation and NF-κB signaling mediate immune responses: hyaluronic acid, LPS, and LTA activate TLR4/TLR2 on intestinal epithelial cells to promote PGE2 secretion and epithelial proliferation, and LGG-secreted p40 proteins stimulate EGFR/NF-κB signaling to upregulate IgA production and repair the intestinal barrier. Third, the Nrf2 pathway manages oxidative stress; SCFAs activate Nrf2 to counteract radiation-induced ROS elevation in epithelial cells.
Beyond the gut, the review highlights remote radiation effects modulated by microbial ecology. Gut-derived L-histidine and its metabolite imidazole propionate (ImP) improved pulmonary and cardiac function in irradiated mice. Indole-3-propionic acid (IPA) expanded thymic and splenic volume and restored hematopoietic stem cell function. Oral microbiota disturbances—particularly colonization by Fusobacterium nucleatum—worsened colorectal cancer radiotherapy resistance. Meanwhile, probiotic cocktails significantly alleviated radiation-induced oral mucositis by modulating the gut microbiome and enhancing immunity.
The review evaluates a spectrum of microbiota-targeted interventions. Probiotics (Lactobacillus, Bifidobacterium species) and prebiotics (SCFAs, dietary fibers) show consistent benefit in preclinical models. Fecal microbiota transplantation (FMT) restores microbial diversity post-radiation. Emerging engineered microbial therapies represent the most advanced frontier, though their clinical translation faces hurdles including therapeutic durability, standardization of microbiome analysis, and individual variability in microbiome composition. The authors call for precision radio-microbiome medicine—personalized radiotherapy strategies guided by individual microbiome profiling—as the next frontier.
Key Findings
- Propionate reduces DNA damage markers (p53, 53BP1) and ROS in irradiated intestinal and bone marrow stem cells.
- Three signaling axes—Wnt/β-catenin, PI3K/AKT/mTOR, and Nrf2—mediate microbial protection against radiation injury.
- Gut-derived imidazole propionate (ImP) and indole-3-propionic acid (IPA) protect cardiac, pulmonary, and hematopoietic systems after irradiation.
- Fusobacterium nucleatum migration from oral to gut microbiota increases colorectal cancer radiotherapy resistance.
- FMT, probiotics, and engineered microbial therapies show promise but face durability and standardization challenges.
Methodology
This is a narrative/systematic review synthesizing preclinical (mouse irradiation models) and clinical evidence across 96 references published up to 2025. The review covers mechanistic signaling pathway analysis alongside evaluation of microbiota-targeted therapeutic interventions. No original experimental data were generated by the authors.
Study Limitations
As a review, causal conclusions are limited by the predominantly preclinical (mouse model) evidence base, with few large-scale human clinical trials. Individual variability in microbiome composition, lack of standardized microbiome analysis methods, and questions about long-term therapeutic durability of microbial interventions remain unresolved challenges.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: